Felicitex Therapeutics Inc. (FLCT)
Felicitex Therapeutics will go public soon, but the exact IPO date is still unknown.
IPO Price
$6.25
Shares Offered
2,480,000
Deal Size
$15.50M

Company Description

Felicitex Therapeutics is a preclinical oncology drug development company focused on developing therapies targeting dormant and active cancer cells.

We have designed and patented small molecules and related methods to selectively disrupt dormant cancer cells in a manner that is specific to the disease and tissue context.

This approach is lethal to cancer cells that rely on deregulation of the cell cycle for survival and has been shown to lead to the reversal of acquired resistance mechanisms.

Our drug candidates are intended to be effective across a broad range of solid tumors and hematological cancers.

We target a high unmet need in large oncology markets including non-small cell lung cancer, glioblastoma multiforme, ovarian, prostate, colorectal, pancreatic cancers, and acute lymphoblastic leukemia.

To date, our business development efforts have consisted of working to discover and identify new therapeutic compounds through our own proprietary drug discovery platform and in collaboration with third parties, and in advancing what we believe to be the most promising of these compounds through preliminary characterization, validation and efficacy studies, both in vitro and in vivo.

We have not obtained regulatory approval for any of our drug candidates and none has yet entered Phase I clinical trials.

We expect to file 2 Investigational New Drug, or IND, applications during the first half of 2023.

Felicitex Therapeutics Inc.
Country United States
Founded 2012
Industry Health Care
Sector Pharmaceuticals
Employees 2
CEO Maria Vilenchik

Contact Details

Address:
27 Strathmore Road
Natick, MA 01760
United States
Phone (919) 213-0025
Website felicitex.com

Stock Details

Ticker Symbol FLCT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $6.25
CIK Code 0001912287
Employer ID 81-1036062
SIC Code 2834

Key Executives

Name Position
Marc Duey Chairman and Director
Maria Vilenchik Chief Executive Officer and Director
Arthur Healey Chief Financial Officer and Secretary
Alex Shlyankevich Director
Yuriy Gankin Director
Michael Frid Director

Latest SEC Filings

Date Type Title
Dec 8, 2022 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Dec 1, 2022 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Oct 31, 2022 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Sep 16, 2022 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Aug 10, 2022 S-1 General form for registration of securities under the Securities Act of 1933
Jul 28, 2022 DRS/A [Amend] [Cover] Draft Registration Statement
Jun 2, 2022 DRS/A [Amend] [Cover] Draft Registration Statement
May 9, 2022 DRS/A [Amend] [Cover] Draft Registration Statement
Mar 22, 2022 DRS [Cover] Draft Registration Statement